Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Kelly L Schoenbeck"'
Autor:
Hannah M. Dragomanovich, Anand Dhruva, Eve Ekman, Kelly L. Schoenbeck, Ai Kubo, Erin L. Van Blarigan, Hala T. Borno, Mikaela Esquivel, Bryant Chee, Matthew Campanella, Errol J. Philip, John P. Rettger, Blake Rosenthal, Katherine Van Loon, Alan P. Venook, Christy Boscardin, Patricia Moran, Frederick M. Hecht, Chloe E. Atreya
Publikováno v:
Global Advances in Health and Medicine, Vol 10 (2021)
Purpose A metastatic cancer diagnosis is associated with high levels of distress in patients and caregivers, which may be alleviated by mindfulness interventions. Research on scalable, tailored, online mindfulness training programs is needed. We soug
Externí odkaz:
https://doaj.org/article/c7915925f8f748679a077124e599447e
Publikováno v:
Cancer Investigation. :1-14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b35639a93a7f1fd7d6111fd6c247338
https://doi.org/10.1080/07357907.2023.2219747
https://doi.org/10.1080/07357907.2023.2219747
Autor:
Mazie Tsang, Kara Elizabeth Bischoff, Kelly L Schoenbeck, Kim Berry, David O'Riordan, Bita Fakhri, Sandy W Wong, Nina Shah, Rebecca L. Olin, Charalambos Andreadis, Jules Vieaux, Eve Cohen, Nancy Shepard Lopez, Gabriel N. Mannis, Michael Rabow
Publikováno v:
Blood Advances.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::132a69b6c32cec0af71f1b5fd8e70bd3
https://doi.org/10.1182/bloodadvances.2022009039
https://doi.org/10.1182/bloodadvances.2022009039
Autor:
Kathryn E. Flynn, Kelly L. Schoenbeck
Publikováno v:
Current Hematologic Malignancy Reports. 16:491-499
Tyrosine kinase inhibitors (TKIs) allow many patients with chronic myeloid leukemia (CML) to live normal life spans but have the potential to impact patients’ health-related quality of life (HRQOL). Patient-reported outcome (PRO) measures can provi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20c89da89631f62af81a70b033240256
https://doi.org/10.1007/s11899-021-00656-y
https://doi.org/10.1007/s11899-021-00656-y
Autor:
Ehab Atallah, Charles A. Schiffer, Jerald P. Radich, Michael J. Mauro, Javier Pinilla-Ibarz, Kelly L. Schoenbeck, Li Lin, Michael W. Deininger, Vamsi Kota, Jorge E. Cortes, Kevin P. Weinfurt, James E. Thompson, Vivian G. Oehler, Neil P. Shah, Richard T. Silver, Kathryn E. Flynn, Richard A. Larson
Publikováno v:
JNCI: Journal of the National Cancer Institute. 114:160-164
Treatment-free remission (TFR) is a goal for patients with chronic myeloid leukemia (CML). Functional outcomes after discontinuing tyrosine kinase inhibitor (TKI) treatment have not been described. Patient-Reported Outcomes Measurement Information Sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d17635c7897fdbc5af8d0df63e35655
https://doi.org/10.1093/jnci/djab184
https://doi.org/10.1093/jnci/djab184
Publikováno v:
Journal of geriatric oncology, vol 12, iss 7
J Geriatr Oncol
J Geriatr Oncol
BACKGROUND: Bortezomib is a common multiple myeloma therapy that can cause treatment-related peripheral neuropathy, a risk factor for falls. The relationship between bortezomib and falls in older patients with multiple myeloma is unknown. METHODS: We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c963f4bf933ca466067b90341c7a929
https://doi.org/10.1016/j.jgo.2021.02.009
https://doi.org/10.1016/j.jgo.2021.02.009
Autor:
Kelly L Schoenbeck, Tanya M Wildes
Publikováno v:
The Lancet. Healthy longevity. 3(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06981926bb7c454d7ed323aa72c2f20
https://pubmed.ncbi.nlm.nih.gov/36102770
https://pubmed.ncbi.nlm.nih.gov/36102770
Autor:
Kelly L. Schoenbeck, Tanya M. Wildes
Publikováno v:
Clinical Interventions in Aging. 15:619-633
Multiple myeloma is a hematologic malignancy that predominantly affects older adults, with a median age at diagnosis of 70 years old. A mainstay of multiple myeloma treatment is lenalidomide, which is an immunomodulatory drug (IMiD) that changed the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca126c7f16287630a75a1025446ad1f7
https://doi.org/10.2147/cia.s196087
https://doi.org/10.2147/cia.s196087
Autor:
Kelly L, Schoenbeck, Kathryn E, Flynn
Publikováno v:
Current hematologic malignancy reportsPapers of particular interest, recently published, are highlighted as: • Of importance. 16(6)
Tyrosine kinase inhibitors (TKIs) allow many patients with chronic myeloid leukemia (CML) to live normal life spans but have the potential to impact patients' health-related quality of life (HRQOL). Patient-reported outcome (PRO) measures can provide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9dc22bd818eec831cc98a148b8830d71
https://pubmed.ncbi.nlm.nih.gov/34648119
https://pubmed.ncbi.nlm.nih.gov/34648119
Autor:
Mazie Tsang, Kara E. Bischoff, Kelly L. Schoenbeck, Kim Berry, David O'Riordan, Bita Fakhri, Sandy Wai Kuan Wong, Nina Shah, Eve Cohen, Nancy Shepard Lopez, Gabriel N. Mannis, Michael W. Rabow
Publikováno v:
Journal of Clinical Oncology. 40:12117-12117
12117 Background: Patients with hematologic malignancies are less likely to receive outpatient palliative care (OPC) compared to patients with other cancer types. Little is known about the characteristics or health care utilization of patients with h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0c77af0ba8cbc181f59e93c47ec67e0
https://doi.org/10.1200/jco.2022.40.16_suppl.12117
https://doi.org/10.1200/jco.2022.40.16_suppl.12117